Immunology/Immunotherapy Program Members
Program Leaders
Victor H.
Engelhard, PhD, Program Co-Leader
Professor, Department of Microbiology
T lymphocyte based immunity to antigens expressed on melanoma and other
tumors.
Craig L.
Slingluff, MD, Program Co-Leader
Professor of Surgery
Cancer vaccines and combination immunotherapy for melanoma, with
evaluation of the cellular immune response and the tumor
microenvironment.
Full Program Members
Reid Adams, MD
Professor, Department of Surgery
Clinical trials of pancreatic cancer vaccine; multidisciplinary
management of pancreatic and hepatobiliary cancers.
Timothy P. Bender,
PhD
Professor, Department of
Microbiology
Lymphocyte development and the regulation of gene expression by c-myb
during hematopoiesis
and lymphomagenesis.
Thomas J. Braciale, MD,
PhD
Professor, Departments of
Pathology and Microbiology
Regulation of CD8 T lymphocyte activation and effector function by
cytokines; Control of T cell
activation within the lung microenvironment.
Michael G. Brown,
PhD
Associate Professor,
Departments of Internal Medicine (Rheumatology) and
Microbiology
NK cells and their receptors in immunity to cytomegalovirus.
Kimberly A. Bullock,
PhD
Assistant Professor of
Surgery
Identification of immunogenic peptides for breast cancer vaccines;
functionality and trafficking
capabilities of vaccine-expanded T cells; immunotherapy trial
design.
Timothy N. J. Bullock,
PhD
Associate Professor, Departments of
Pathology and Microbiology
Increasing the presence and function of T cells in the tumor
microenvironment; impact of CD70-CD27 co-stimulation on T cell
function; function of CD4 T cells in enhancing CD8 T cell recruitment
to tumors.
John Densmore, MD, PhD
Associate Professor, Department of Internal Medicine (Hematology and
Oncology)
Clinical investigations of new targeted therapies in multiple
myeloma.
Loren D. Erickson,
PhD
Assistant Professor, Department of
Microbiology
Processes that control commitment of antigen-stimulated B cells to
become long-lived plasma cells and that control development and
progression of malignant plasma cells.
Joanna B. Goldberg,
PhD
Professor, Department of Microbiology
Pathogenesis of Helicobacter pylori; development of vaccine to protect
against Pseudomonas aeruginosa, a major pathogen affecting individuals
undergoing cancer chemotherapy.
Adam N. Goldfarb, MD
Professor, Department of
Pathology
Erythroid and megakaryocytic differentiation to identify new approaches
toward treatment of anemias and thrombocytopenias in cancer patients
and to shed light on the pathogenesis of megakaryocytic leukemias.
William W. Grosh, MD
Associate Professor, Department of
Internal Medicine (Hematology and Oncology)
Clinical trials of immunologic and targeted therapies for melanoma.
Young S. Hahn, PhD
Professor, Department of
Microbiology
Immunoregulatory mechanisms employed by Hepatitis C virus to evade host
immunity and
establish persistent infection leading to hepatocellular carcinoma.
Dean H. Kedes, MD,
PhD
Associate Professor, Departments of
Internal Medicine (Infectious Diseases) and
Microbiology
Kaposi’s sarcoma virus – tumorigenesis, immune responses and viral
immune evasion mechanisms.
Tracey Krupski, MD,
MPH
Assistant Professor, Department of Urology
Role of interferon-inducible CXC chemokines and CXCR3 in therapeutic
effect of intravesical BCG therapy for bladder cancer; clinical
investigation of adenosine inhibition to modulate the tumor response to
BCG.
Mary Laughlin, MD
Professor, Department of Internal
Medicine (Hematology and Oncology
Umbilical cord blood hematopoetic stem cell
transplantation for treatment of hematologic malignancies; T-cell
biology relevant to allogeneic transplantation; novel phase I studies
on umbilical cord blood transplantation.
Ulrike M. Lorenz, PhD
Associate Professor, Department of
Microbiology
SHP-1 signaling pathways that influence T cell development and
activation with a special focus on regulatory T cells and TH17 cells
and how they affect tumor immunity.
Kodi S. Ravichandran,
PhD
Professor, Department of
Microbiology
Intracellular signaling pathways in hematopoietic cells and their
regulation of growth and differentiation; control of apoptosis and the
role of cell clearance pathways in cancer, differentiation and
inflammation.
Ronald P. Taylor, PhD
Professor, Department of
Biochemistry and Molecular Genetics
Mechanisms of action of anti-tumor monoclonal antibodies.
Kenneth S.K. Tung, MD
Professor, Departments of Pathology
and Microbiology
Mechanisms of tolerance and autoimmune response to testis specific
antigens as a model to understand immunity to human cancer-testes
antigens.
Geoffrey R. Weiss,
MD
Professor and Division Chief, Department of Internal Medicine
(Hematology and Oncology)
Clinical investigations of immunotherapy and new targeted therapies for
malignant melanoma and GU malignancies.
Michael E. Williams, MD
Professor, Department of Internal Medicine
(Hematology and Oncology)
Clinical and translational research of novel therapeutics and
prognostic biomarkers in hematologic malignancies, with a focus in
non-Hodgkin lymphoma and chronic lymphocytic leukemia.
Associate Program Members
Michael G. Douvas, MD
Assistant Professor, Department of
Medicine, Hematology and Oncology
Core binding factor, targeted therapy for leukemia, young adult
oncology
John C. Herr, PhD
Director, Center for Research in Contraceptive and Reproductive
Health; Professor, Department of Cell Biology
Thomas A.
Platts-Mills, MD, PhD
Professor of Internal Medicine
(Allergy and Clinical Immunology)
Preexisting IgE responses to the carbohydrates on humanized monoclonal
antibodies used for cancer immunotherapy that can cause severe allergic
responses in cancer patients, develop screening assays to avoid these
reactions.
Angela L. Zarling, PhD
Research Assistant Professor of
Microbiology
T cell receptors that are specific for phosphopeptides, with the
ultimate goal of using them to transduce T cells for adoptive cellular
therapy.
